Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
STRO 
Sutro Biopharma (STRO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: STRO (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
10 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $2.69
1 Year Target Price $2.69
| 4 | Strong Buy |
| 0 | Buy |
| 5 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -57.63% | Avg. Invested days 22 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 75.58M USD | Price to earnings Ratio - | 1Y Target Price 2.69 |
Price to earnings Ratio - | 1Y Target Price 2.69 | ||
Volume (30-day avg) 10 | Beta 1.58 | 52 Weeks Range 0.52 - 4.60 | Updated Date 09/16/2025 |
52 Weeks Range 0.52 - 4.60 | Updated Date 09/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.51 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -199.76% | Operating Margin (TTM) 23.65% |
Management Effectiveness
Return on Assets (TTM) -27.54% | Return on Equity (TTM) -347.64% |
Valuation
Trailing PE - | Forward PE 9.91 | Enterprise Value -109953344 | Price to Sales(TTM) 0.72 |
Enterprise Value -109953344 | Price to Sales(TTM) 0.72 | ||
Enterprise Value to Revenue 0.36 | Enterprise Value to EBITDA 0.41 | Shares Outstanding 84774200 | Shares Floating 67164037 |
Shares Outstanding 84774200 | Shares Floating 67164037 | ||
Percent Insiders 4.55 | Percent Institutions 62.93 |
Upturn AI SWOT
Sutro Biopharma
Company Overview
History and Background
Sutro Biopharma was founded in 2003 and is focused on the discovery, development, and manufacturing of cancer and autoimmune disease therapeutics. They utilize their XpressCF and integrated cell-free protein synthesis platform to create targeted therapies.
Core Business Areas
- Drug Discovery and Development: Focuses on identifying and developing novel therapies for cancer and autoimmune diseases.
- XpressCF Platform: Their cell-free protein synthesis platform used to rapidly discover and develop novel molecules.
- Clinical Trials: Conducting clinical trials to evaluate the safety and efficacy of their drug candidates.
- Partnerships and Collaborations: Collaborating with other pharmaceutical companies to develop and commercialize their therapies.
Leadership and Structure
The leadership team consists of experienced professionals in the biotechnology and pharmaceutical industries. The organizational structure is comprised of research and development, clinical operations, and administrative functions.
Top Products and Market Share
Key Offerings
- STRO-002: An antibody-drug conjugate (ADC) targeting folate receptor alpha (FolRu03b1) for ovarian cancer and endometrial cancer. Currently in clinical trials. There is no current Market Share data available. Competitors are ImmunoGen (ELAHERE), and GSK (Blenrep ADC). The market is focused on patients who progressed on chemotherapy.
- STRO-001: An antibody-drug conjugate (ADC) targeting CD74 for hematological malignancies. Currently in clinical trials. There is no current Market Share data available. Competitors are ADC Therapeutics and Seagen. The market is focused on lymphoma and multiple myeloma
- CC-99712: A BCMA-targeting ADC being developed in collaboration with Bristol Myers Squibb for multiple myeloma. Currently in clinical trials. There is no current Market Share data available. Competitors are GSK (Blenrep ADC) and multiple myeloma therapies.
Market Dynamics
Industry Overview
The biotechnology industry is characterized by high innovation, long development cycles, and significant regulatory hurdles. There is intense competition and high financial risk.
Positioning
Sutro Biopharma is positioned as a leader in cell-free protein synthesis and ADC development. Their XpressCF platform offers advantages in speed and flexibility compared to traditional methods.
Total Addressable Market (TAM)
The TAM for cancer and autoimmune disease therapeutics is estimated to be in the hundreds of billions of dollars. Sutro is focused on targeted therapies within those spaces.
Upturn SWOT Analysis
Strengths
- Proprietary XpressCF platform
- Experienced management team
- Strong pipeline of ADC candidates
- Partnerships with major pharmaceutical companies
Weaknesses
- High cash burn rate
- Dependence on clinical trial success
- Limited commercial infrastructure
- Competition from larger pharmaceutical companies
Opportunities
- Expansion of ADC pipeline
- Successful clinical trial outcomes
- New partnerships and collaborations
- Advancements in cell-free protein synthesis
Threats
- Clinical trial failures
- Regulatory delays
- Competition from other therapies
- Economic downturn
Competitors and Market Share
Key Competitors
- ImmunoGen (IMGN)
- ADC Therapeutics (ADCT)
- Seagen (SGEN)
Competitive Landscape
Sutro Biopharma competes with larger pharmaceutical companies and specialized ADC developers. Their XpressCF platform provides a competitive advantage. There is no current Market Share data available.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by collaborations and milestone payments.
Future Projections: Future growth depends on clinical trial success and regulatory approvals. Analyst estimates vary widely. The average target stock price is $9.50 as of May 2024 according to Marketwatch.
Recent Initiatives: Focusing on advancing their ADC pipeline and expanding their XpressCF platform capabilities.
Summary
Sutro Biopharma is a clinical-stage biotech company with a promising ADC platform and pipeline. While their financials reflect the high cash burn typical of biotech, their collaborations validate their technology. Clinical trial success is paramount to their future. The company faces stiff competition and regulatory risks, but also holds growth opportunities through pipeline expansion and partnerships.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Sutro Biopharma Investor Relations
- SEC Filings (10-K, 10-Q)
- Analyst Reports
- Company Press Releases
- MarketWatch
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Investment decisions should be based on your own research and risk tolerance. The data may be delayed and is not guaranteed to be accurate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Sutro Biopharma
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2018-09-27 | CEO & Director Ms. Jane Chung R.Ph. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 244 | Website https://www.sutrobio.com |
Full time employees 244 | Website https://www.sutrobio.com | ||
Sutro Biopharma, Inc. operates as a oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conjugation platform, XpressCF+. Its lead product candidate includes STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. The company also develops VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors, such as triple negative breast cancer, non-small cell lung cancer, and ovarian cancer, as well as hematological cancers. Sutro Biopharma, Inc. has collaboration and license agreements with Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; Ipsen to develop and commercialize STRO-003, an ADC targeting ROR1; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.